Part 2- 8 Renowned Hepatology Experts Answer 32 Questions On Hepatitis C

ClinicalQuiz: So You Think You’re a Hepatitis C Expert

Hello folks,
Back in July Clinical Care Options released part one of a three part online quiz containing 35 questions on hepatitis C, answered by nine world-renowned hepatology experts. Today CCO released part two, links and a description are provided below with a sample question from the second part of "So You Think You’re a Hepatitis C Expert." For more details of the quiz itself, please visit clinicaloptions.com/HCVquiz.

*Free registration is required

Part One
Now participants can answer part one of the hepatitis C case-based questions on an iPad*, iPhone* and Android or online-by clicking here .
* To install this app, please visit this page using your iPhone or iPad's Web browser.

ClinicalQuiz: Part 1 - So You Think You’re a Hepatitis C Expert, Educational Material

Explore a collection of clinical pearls on HCV management in this series of case scenarios from 11 leading international experts on hepatitis C.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify best practices for the treatment of hepatitis C with approved agents including boceprevir, telaprevir, peginterferon, and ribavirin
  • Assess and monitor the individualized care of patients receiving HCV therapy to address adverse events, adherence, and other issues
  • Evaluate the impact of emerging data on investigational HCV agents for the management of patients with hepatitis C today and in the future
  • Assess and identify potential drug-drug interactions prior to the initiation of HCV protease inhibitor-based therapy
Part Two

This CME-certified activity provides clinical management insights from leading experts on the care of patients with hepatitis C.

Below is one example of the 32 questions found in the quiz:

Patient Case: Retreatment of a Null Responder With Telaprevir
The patient is a 47-year-old woman with genotype 1 HCV infection. She was previously treated 2 years ago with peginterferon and ribavirin and experienced a null response but treatment was well tolerated. She has a close friend who died from HCV-related liver disease and thus is very motivated to receive retreatment in hopes of clearing the virus. A current liver biopsy reveals stage 2 fibrosis. At current baseline, her HCV RNA level is 2.5 x 106 IU/mL. The patient begins telaprevir-based therapy with 12 weeks of triple therapy with telaprevir plus peginterferon/ribavirin. After 4 weeks, her HCV RNA level is undetectable and it remains so at Week 12.

What course of therapy should you follow for this patient, assuming no futility rules are breached?

Analysis by Paul J. Pockros, MD:This patient should continue peginterferon/ribavirin therapy through Week 48. According to the prescribing information, all previous null responders, regardless of on-treatment response pattern, should receive a regimen consisting of 12 weeks of peginterferon/ribavirin plus telaprevir therapy followed by 36 weeks of dual peginterferon/ribavirin.[3] Had she been treatment naive or a previous relapser, this on-treatment response would enable her to stop therapy at Week 24. Had she been a previous partial responder with this response, her course would have been the same as null responders and she would have needed 48 total weeks of treatment.....

Other Questions...
Patient Case: Management of Rash in a Patient Receiving Telaprevir
Patient Case: Management of Hair Loss During Boceprevir Therapy
Case: Management of Anorectal Symptoms in a Patient Receiving Telaprevir
Patient Case: Management of HCV in an Elderly Man..............

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify best practices for the treatment of hepatitis C with approved agents including boceprevir, telaprevir, peginterferon, and ribavirin
  • Assess and monitor the individualized care of patients receiving HCV therapy to address adverse events, adherence, and other issues
  • Evaluate the impact of emerging data on investigational HCV agents for the management of patients with hepatitis C today and in the future
  • Assess and identify potential drug–drug interactions prior to the initiation of HCV protease inhibitor–based therapy

Part 3 - Coming Soon
Click here for more information

0 comments:

Post a Comment